前列腺特异性抗原应如何解读？
How should prostate specific antigen be interpreted?
作者信息
Atan Ali, Güzel Özer
机构信息
Department of Urology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
出版信息
Turk J Urol. 2013 Sep;39(3):188-93. doi: 10.5152/tud.2013.038.
Abstract
Since from its clinical introduction to the present time, measurement of serum prostate specific antigen (PSA) level is one of the most widely used tests in urology practice. Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years of age and younger. On the use of PSA as a screening test for prostate cancer, there are differences of opinion. However, it is a recommended test in the evaluation and monitoring of the risky group for prostate cancer. In conclusion PSA test should be performed at appropriate intervals for appropriate people with an appropriate age, after informing the patient about the test in detail.
摘要
自从血清前列腺特异性抗原（PSA）水平检测在临床上应用至今，它一直是泌尿外科实践中使用最广泛的检测方法之一。最初，PSA的上限值为4 ng/mL，但如今，对于60至65岁及以下的患者，建议将上限值降至2.5 - 3 ng/mL。关于将PSA用作前列腺癌筛查检测，存在不同意见。然而，在评估和监测前列腺癌风险人群时，它是一项推荐检测。总之，在向患者详细告知检测情况后，应针对合适年龄的合适人群，以适当的间隔进行PSA检测。
相似文献
1
How should prostate specific antigen be interpreted?前列腺特异性抗原应如何解读？
Turk J Urol. 2013 Sep;39(3):188-93. doi: 10.5152/tud.2013.038.
2
[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age].[泌尿外科实践中前列腺癌的检测：按年龄建立血清前列腺特异抗原参考值的临床研究]
Nihon Hinyokika Gakkai Zasshi. 1996 Mar;87(3):702-9. doi: 10.5980/jpnjurol1989.87.702.
3
4
5
Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.前列腺腺癌筛查中正常范围前列腺特异性抗原与年龄特异性前列腺特异性抗原的比较
Urology. 1995 Aug;46(2):200-4. doi: 10.1016/s0090-4295(99)80194-0.
6
7
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.游离前列腺特异性抗原百分比的诊断价值：一项基于人群的筛查研究的回顾性分析，重点关注前列腺特异性抗原水平低于3.0 ng/mL的男性。
Urology. 1999 May;53(5):945-50. doi: 10.1016/s0090-4295(98)00640-2.
8
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.用于检测可治愈前列腺癌的推荐前列腺特异性抗原检测间隔时间。
JAMA. 1997 May 14;277(18):1456-60.
9
Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.通过前列腺特异性抗原（PSA）进行前列腺癌筛查；对开曼群岛的少数人群而言是一种切实可行的方法。
Cancer Causes Control. 2018 Jan;29(1):87-92. doi: 10.1007/s10552-017-0963-2. Epub 2017 Sep 16.
10
Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.游离、复合及总血清前列腺特异性抗原：确定其浓度及比值的合适参考范围。
J Urol. 1995 Sep;154(3):1090-5. doi: 10.1016/s0022-5347(01)66984-2.
引用本文的文献
1
Nucleic Acid Aptamer-Based Biosensors: A Review.基于核酸适配体的生物传感器：综述
Biomedicines. 2023 Dec 1;11(12):3201. doi: 10.3390/biomedicines11123201.
2
Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania.前列腺动脉栓塞术作为治疗症状性良性前列腺增生的一种选择：来自立陶宛前瞻性随访研究的结果。
Medicina (Kaunas). 2023 Oct 21;59(10):1871. doi: 10.3390/medicina59101871.
3
Breviscapine Participates in the Progression of Prostate Cancer by Inhibiting ZFP91 Expression through Upregulation of MicroRNA-129-5p.灯盏花素通过上调MicroRNA-129-5p抑制ZFP91表达参与前列腺癌进展。
Evid Based Complement Alternat Med. 2021 Dec 8;2021:1511607. doi: 10.1155/2021/1511607. eCollection 2021.
4
MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.微小 RNA-498 通过靶向 PTEN 促进前列腺癌细胞的增殖、迁移和侵袭，并降低其辐射敏感性。
Kaohsiung J Med Sci. 2019 Nov;35(11):659-671. doi: 10.1002/kjm2.12108. Epub 2019 Jul 22.
5
Multiparametric prostatic MRI should not be the only method to decide re-biopsy in the patients who had a negative prostatic biopsy.对于前列腺穿刺活检结果为阴性的患者，多参数前列腺MRI不应是决定再次活检的唯一方法。
Int Urol Nephrol. 2019 Oct;51(10):1781-1782. doi: 10.1007/s11255-019-02227-w. Epub 2019 Jul 9.
6
Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients.镓-68 PSMA 正电子发射断层扫描/计算机断层扫描与 Tc-99m MDP 骨扫描在前列腺癌患者中的比较。
Turk J Med Sci. 2019 Feb 11;49(1):301-310. doi: 10.3906/sag-1807-4.
7
Using Sigma metrics to establish analytical product performance requirements and optimize analytical performance of an diagnostic assay using a theoretical total PSA assay as an example.使用西格玛度量来建立分析产品性能要求，并优化诊断分析的分析性能，以理论总 PSA 分析为例。
Biochem Med (Zagreb). 2018 Jun 15;28(2):020903. doi: 10.11613/BM.2018.020903.
8
Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population.韩国人群中表皮生长因子和表皮生长因子受体多态性与良性前列腺增生的关联研究
Int Neurourol J. 2016 Dec;20(4):363-370. doi: 10.5213/inj.1632538.269. Epub 2016 Dec 26.
本文引用的文献
1
Prostate specific antigen best practice statement: 2009 update.前列腺特异性抗原最佳实践声明：2009 年更新。
J Urol. 2013 Jan;189(1 Suppl):S2-S11. doi: 10.1016/j.juro.2012.11.014.
2
Informed prostate cancer risk-adjusted testing: a new paradigm.知情前列腺癌风险调整检测：一种新范式。
BJU Int. 2012 Dec;110 Suppl 4:30-4. doi: 10.1111/j.1464-410X.2012.11621.x.
3
Risk-based prostate cancer screening.基于风险的前列腺癌筛查。
Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24.
4
Randomised prostate cancer screening trial: 20 year follow-up.随机前列腺癌筛查试验：20 年随访。
BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.
5
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
6
PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.基于 PSA 的前列腺癌筛查：主动监测的作用以及知情和共同决策。
Asian J Androl. 2011 Mar;13(2):219-24. doi: 10.1038/aja.2010.180. Epub 2011 Feb 7.
7
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.主动监测与初始治疗比较用于低危前列腺癌患者：决策分析。
JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720.
8
Use and assessment of PSA in prostate cancer.在前列腺癌中使用和评估 PSA。
Med Clin North Am. 2011 Jan;95(1):191-200. doi: 10.1016/j.mcna.2010.08.024.
9
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.EAU 前列腺癌指南。第 1 部分：局限性疾病的筛查、诊断和治疗。
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
10
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
Zotero 插件